Dr. Jake Scott is a board-certified infectious diseases specialist. He provides general infectious diseases care in the inpatient and outpatient settings and his special interests include COVID-19, coccidiomycosis, multidrug-resistant organisms, HIV, and HIV pre-exposure prophylaxis. He works with patients from diverse backgrounds to provide compassionate, high-quality care aligned with their needs.

Dr. Scott was born and raised in the Bay Area and was inspired to pursue a career in medicine after working as an HIV test counselor in San Francisco. He studied literature and creative writing in college and values the narrative aspect of medicine and the importance of drawing out the story behind the diagnosis.

One of Dr. Scott’s passions is teaching. He regularly works with Stanford residents and students and has lectured on various infectious disease-related topics, such as COVID-19, fever of unknown origin, and the dangers of antibiotic overuse, especially as it contributes to the rising threat of multidrug-resistant infections. He is also committed to expanding awareness of infectious diseases outside of the hospital and university through public presentations in the community and media interviews.
He is co-medical director of the Antibiotic Stewardship Program at Stanford Health Care – ValleyCare in Pleasanton and member of the Infection Control Committee.

In his spare time, Dr. Scott enjoys rock climbing, hiking, and spending time with his two young children.

Clinical Focus

  • Infectious Disease

Academic Appointments

Boards, Advisory Committees, Professional Organizations

  • Member, Infectious Diseases Society of America (2013 - Present)
  • Member, Society for Healthcare Epidemiology of America (SHEA) (2015 - Present)

Professional Education

  • Fellowship, UCLA Infectious Diseases Fellowship, CA (2016)
  • Residency: Kaiser Permanente Oakland Internal Medicine Residency (2014) CA
  • Medical Education: University of Vermont College of Medicine (2011) VT
  • Board Certification: American Board of Internal Medicine, Infectious Disease (2016)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2014)


All Publications

  • Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, northern California, USA, March–April 2020 Emerging Infectious Diseases Ferguson, J., Rosser, J., Quintero, O., Scott, J., Subramanian, A., Gumma, M., Rogers, A., Kappagoda, S. 2020


    Limited data are available on the clinical presentation and outcomes of coronavirus disease (COVID-19) patients in the United States hospitalized under normal-caseload or nonsurge conditions. We retrospectively studied 72 consecutive adult patients hospitalized with COVID-19 in 2 hospitals in the San Francisco Bay area, California, USA, during March 13-April 11, 2020. The death rate for all hospitalized COVID-19 patients was 8.3%, and median length of hospitalization was 7.5 days. Of the 21 (29% of total) intensive care unit patients, 3 (14.3% died); median length of intensive care unit stay was 12 days. Of the 72 patients, 43 (59.7%) had underlying cardiovascular disease and 19 (26.4%) had underlying pulmonary disease. In this study, death rates were lower than those reported from regions of the United States experiencing a high volume of COVID-19 patients.

    View details for DOI 10.3201/eid2608.201776

  • Recurrent Multifocal Mycoplasma orale Infection in an Immunocompromised Patient: A Case Report and Review. Case reports in infectious diseases Ketchersid, J., Scott, J., Lew, T., Banaei, N., Kappagoda, S. 2020; 2020: 8852115


    A young woman with mixed connective tissue disease complicated by erosive arthritis, secondary hypogammaglobulinemia due to rituximab, and a history of many infectious complications developed multiple nonhealing wounds, polyarticular joint pain, and leukocytosis. Radiographic studies demonstrated multiple scattered areas of osteomyelitis and complex abscesses. Purulent fluid drained from multiple sites did not yield a microbiologic diagnosis by standard culture technique, but Mycoplasma orale was ultimately identified using 16S ribosomal RNA gene amplification and sequencing. We describe this unique case and review the literature.

    View details for DOI 10.1155/2020/8852115

    View details for PubMedID 32850161

  • Treatment optimization for HIV/HCV co-infected patients. Therapeutic advances in infectious disease Scott, J. A., Chew, K. W. 2017; 4 (1): 18-36


    Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections affect millions of persons around the globe and cause profound morbidity and mortality. A major intersection exists between these two epidemics, with HCV infection being more common in persons with HIV than in the general population, largely due to shared routes of transmission. HCV co-infection increases risk for liver- and non-liver-related morbidity and mortality, making HCV treatment a priority in HIV co-infected persons, but the treatment of HCV in co-infected patients has been daunting for multiple reasons. Until recently, HCV treatment has frequently been deferred due to the low rates of cure, significant adverse effects, burdensome duration of therapy and drug-drug interactions with HIV antiretroviral medications. Untreated HCV has resulted in significant health consequences for the millions of those infected and has led to multiple downstream impacts on our healthcare systems around the world. The development of a remarkable number of new HCV direct-acting agents (DAAs) that are significantly more efficacious and tolerable than the previous interferon-based regimens has transformed this important field of medicine, with the potential to dramatically reduce the burden of infection and improve health outcomes in this population. This review will summarize the epidemiology and clinical impact of HIV/HCV co-infection and current approaches to the treatment of HCV in HIV/HCV co-infected patients.

    View details for DOI 10.1177/2049936116681279

    View details for PubMedID 28357062

Latest information on COVID-19